中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents

Construction of a goal-oriented efficacy evaluation system for traditional Chinese medicine in the prevention and treatment of primary liver cancer

DOI: 10.12449/JCH260504
Research funding:

National Science and Technology Major Project (2024ZD0526200)

More Information
  • Corresponding author: LU Yinying, luyinying1973@163.com (ORCID: 0000-0002-7737-2334)
  • Received Date: 2026-03-22
  • Accepted Date: 2026-04-22
  • Published Date: 2026-05-25
  • Traditional Chinese medicine (TCM) plays an important role in the full-cycle management of primary liver cancer; however, the current evidence-based evaluation system with the main assessment index of objective tumor remission is mainly centered on randomized controlled trials and systematic reviews/meta-analyses and cannot fully reflect the characteristics and advantages of TCM. Based on the current status of TCM efficacy evaluation in the prevention and treatment of liver cancer, this article proposes the construction of a multi-dimensional evaluation system that is oriented by stage-specific treatment goals and integrates outcome indicators with process indicators. Outcome indicators include modern medical endpoints such as overall survival and recurrence-free survival, and process indicators include short-term outcomes such as the improvement in TCM syndrome, patient-reported outcomes, the remission rate of adverse events, and the discontinuation rate of the core regimen. It is emphasized that the development of standardized TCM regimens should follow the order of theoretical connotation, accumulation of proven cases, observational evaluation, and interventional evaluation. Furthermore, it is recommended to incorporate artificial intelligence approaches into this evaluation system, so as to promote the intelligent and precise assessment of TCM efficacy.

     

  • loading
  • [1]
    Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. J Clin Hepatol, 2025, 41( 7): 1279- 1286. DOI: 10.12449/JCH250709.

    中国抗癌协会肝癌专业委员会. 中国肝癌多学科综合治疗专家共识(2025年版)[J]. 临床肝胆病杂志, 2025, 41( 7): 1279- 1286. DOI: 10.12449/JCH250709.
    [2]
    Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.

    中华中医药学会肝胆病分会. 原发性肝癌中医诊疗指南[J]. 临 床肝胆病杂志, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.
    [3]
    JI D, CHEN Y, BI JF, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77( 6): 1515- 1524. DOI: 10.1016/j.jhep.2022.07.018.
    [4]
    CHEN Q, SHU C, LAURENCE AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: A multicentre, randomised clinical trial[J]. Gut, 2018, 67( 11): 2006- 2016. DOI: 10.1136/gutjnl-2018-315983.
    [5]
    FENG QT, HU JJ, YU S, et al. Efficacy of Jiedu formula(解毒方) as adjuvant therapy for early recurrence of hepatocellular carcinoma after radical surgery: A propensity score matching study[J]. J Tradit Chin Med, 2025, 45( 2): 443- 449. DOI: 10.19852/j.cnki.jtcm.2025.02.019.
    [6]
    YUAN HX, NIU QQ, SHANG XF, et al. Impact of traditional Chinese medicine on prognosis of patients with hepatocellular carcinoma: A retrospective cohort study[J]. Integr Cancer Ther, 2023, 22: 15347354231170536. DOI: 10.1177/15347354231170536.
    [7]
    YU Y, WU TT, WU MR, et al. Evidence map of traditional Chinese exercises[J]. Front Public Health, 2024, 12: 1347201. DOI: 10.3389/fpubh.2024.1347201.
    [8]
    MUZELLEC L, BOURIEN H, EDELINE J. Patients’ experience of systemic treatment of hepatocellular carcinoma: A review of the impact on quality of life[J]. Cancers(Basel), 2021, 14( 1): 179. DOI: 10.3390/cancers14010179.
    [9]
    CHUNG EZ, SFERRAZZA D, LEE SF, et al. Comparing FACT and EORTC QLQ modules for the assessment of quality of life in patients with hepatobiliary cancers[J]. Curr Opin Support Palliat Care, 2025, 19: 203- 213. DOI: 10.1097/SPC.0000000000000764.
    [10]
    YU GH, SONG CY, SONG X. Effect evaluation of Kushen Huangqi decoction combined with Aidi injection in the treatment of primary liver cancer[J]. Tianjin Med J, 2025, 53( 4): 429- 433. DOI: 10.11958/20242336.

    于光华, 宋春燕, 宋雪. 苦参黄芪汤联合艾迪注射液治疗原发性肝癌的效果评价[J]. 天津医药, 2025, 53( 4): 429- 433. DOI: 10.11958/20242336.
    [11]
    CHENG Y, WANG HY, WAN CY, et al. Efficacy and safety of Erzhu Jiedu Decoction Granules in treating mid-advanced hepatitis B virus-associated primary liver cancer patients with Pi(Spleen)-deficiency and dampness-heat syndrome[J]. Chin J Integr Med, 2025, 31: 394- 401. DOI: 10.1007/s11655-024-3818-1.
    [12]
    YAN HT, LI YJ, GUO B, et al. The effect of traditional Chinese medicine on patients undergoing targeted therapy for primary liver cancer: a systematic review and meta-analysis[J]. Front Oncol, 2025, 15: 1674965. DOI: 10.3389/fonc.2025.1674965.
    [13]
    CHEN XL, WANG P, YANG MD, et al. Therapeutic effect of Jianpi Liqi Fang combined with transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and spleen deficiency syndrome[J]. J Tradit Chin Med, 2021, 41: 157- 166. DOI: 10.19852/j.cnki.jtcm.2021.01.018.
    [14]
    KONG Y, ZHU XN, ZHANG X, et al. Traditional Chinese medicine combined with radiofrequency ablation improves primary liver cancer outcomes: A systematic review with meta-analysis[J]. Heliyon, 2023, 9: e18591. DOI: 10.1016/j.heliyon.2023.e18591.
    [15]
    PU Q, YU LH, WANG XH, et al. Immunomodulatory effect of traditional Chinese medicine combined with systemic therapy on patients with liver cancer: A systemic review and network meta-analysis[J]. J Cancer, 2022, 13( 11): 3280- 3296. DOI: 10.7150/jca.74829.
    [16]
    ZHOU TH, ZHANG YY, LU YQ, et al. The efficacy of combined use of Huaier Granules in the treatment of primary liver cancer: An updated systematic review and meta-analysis[J]. Pharmaceuticals(Basel), 2025, 18( 6): 884. DOI: 10.3390/ph18060884.
    [17]
    CHAN T, YE CY, GUO H Y, et al. Liver elastography-based risk score for predicting hepatocellular carcinoma risk[J]. J Natl Cancer Inst, 2025, 117( 4): 761- 771. DOI: 10.1093/jnci/djae304.
    [18]
    CHOI J, NGUYEN VH, PRZYBYSZEWSKI E, et al. Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease[J]. JAMA Intern Med, 2025, 185( 5): 522- 530. DOI: 10.1001/jamainternmed.2025.0115.
    [19]
    FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73( 6): 1368- 1378. DOI: 10.1016/j.jhep.2020.07.025.
    [20]
    WANG YY, LIN WF, HUANG GK, et al. The therapeutic principle of combined clearing heat and resolving toxin plus TACE on primary liver cancer: A systematic review and meta-analysis[J]. J Ethnopharmacol, 2024, 319( Pt 1): 117072. DOI: 10.1016/j.jep.2023.117072.
    [21]
    YANG Y, SUN MY, YAO WB, et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib[J]. J Immunother Cancer, 2020, 8( 1): E000317. DOI: 10.1136/jitc-2019-000317.
    [22]
    CUI Z, WANG HJ, LI S, et al. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism[J]. J Pharmacol Sci, 2022, 148: 73- 85. DOI: 10.1016/j.jphs.2021.09.008.
    [23]
    LUO Y, ZHAO X, WANG RL, et al. Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines(Eff-iEC): A demonstration study[J]. Acta Pharm Sin B, 2025, 15( 2): 909- 918. DOI: 10.1016/j.apsb.2024.12.024.
    [24]
    ZHANG P, ZHANG Q, LI S. Advancing cancer prevention through an AI-based integration of traditional and western medicine[J]. Cancer Discov, 2024, 14( 11): 2033- 2036. DOI: 10.1158/2159-8290.CD-24-0832.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (33) PDF downloads(16) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return